Gore touts Viabahn endoprosthesis superiority over PTA in new study
W.L. Gore & Associates today released results from a clinical study of its Viabahn endoprosthesis in AV access graft outflow interventions, touting a 50% increase over percutaneous transluminal angioplasty alone in target lesion primary patency at 6 months. The company reported that treatment with the Viabahn resulted in significantly better outcomes when compared against PTA alone for treating challenging AV access cases, both in terms of primary patency and number of interventions during the study period. Results from the study were published in the Journal of Vascular Surgery, Newark, Del.-based Gore said. “Patients with failing dialysis circuits that are unresponsive to balloon angioplasty are a real problem for physicians. Historically, angioplasty has been a popular treatment option, but our study found its 6-month primary patency rates to be well below the ‘reasonable goal’ of 50% stated by the 2006 K/DOQI Guidelines for Vascular Access. The data shown in the Gore Revise clinical study manuscript makes a compelling argument for Gore Viabahn Endoprosthesis use in those challenging cases,” primary author Dr. Thomas Vesely of St. Louis, Mo.’s Vascular Access Services said in a prepared statement. Data from the study also indicated a 47% improvement in target lesion primary patency and a 48% improvement in circuit primary patency when compared against PTA alone at 6 months. In elbow placements, data indicated a 72% target lesion primary patency at...
Source: Mass Device - Category: Medical Equipment Authors: Fink Densford Tags: Catheters Clinical Trials Vascular W.L. Gore & Associates Source Type: news
More News: Angioplasty | Baloon Angioplasty | Clinical Trials | Dialysis | Medical Devices | Peripheral Angioplasty | Study